WOW · As filed with the SEC
WideOpenWest cash flow statement, by quarter
The statement as WideOpenWest presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS · USD
| USD | Q3 2025 3 months ended Sep 30, 2025 | Q2 2025 3 months ended Jun 30, 2025 | Q1 2025 3 months ended Mar 31, 2025 | Q4 2024 3 months ended Dec 31, 2024 | Q3 2024 3 months ended Sep 30, 2024 | Q2 2024 3 months ended Jun 30, 2024 | Q1 2024 3 months ended Mar 31, 2024 | Q4 2023 3 months ended Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||
| Net loss | — | — | (13,900,000) | — | — | — | (15,000,000) | — |
| Adjustments to reconcile net loss to net cash provided by operating activities: | ||||||||
| Depreciation and amortization | — | — | 52,100,000 | — | — | — | 52,700,000 | — |
| Deferred income taxes | — | — | 3,900,000 | — | — | — | (1,400,000) | — |
| Provision for doubtful accounts | — | — | — | — | — | — | 2,700,000 | — |
| Loss on sale of operating assets, net | — | — | — | — | — | — | (300,000) | — |
| Provision for credit losses | — | — | 2,000,000 | — | — | — | — | — |
| Gain (loss) on sale of operating assets, net | — | — | (1,300,000) | — | — | — | — | — |
| Amortization of debt issuance costs and discount | — | — | 1,500,000 | — | — | — | 400,000 | — |
| Change in fair value of derivative instruments | — | — | 2,800,000 | — | — | — | 1,100,000 | — |
| Non-cash compensation | — | — | 2,400,000 | — | — | — | 3,000,000 | — |
| Other non-cash items | — | — | — | — | — | — | (200,000) | — |
| Changes in operating assets and liabilities: | ||||||||
| Receivables and other operating assets | — | — | (10,900,000) | — | — | — | (6,000,000) | — |
| Payables and accruals | — | — | (21,900,000) | — | — | — | (3,800,000) | — |
| Net cash provided by operating activities | — | — | 16,700,000 | — | — | — | 33,200,000 | — |
| Cash flows from investing activities: | ||||||||
| Capital expenditures | — | — | (38,900,000) | — | — | — | (72,500,000) | — |
| Other investing activities | — | — | 1,200,000 | — | — | — | — | — |
| Net cash used in investing activities | — | — | (37,700,000) | — | — | — | (72,500,000) | — |
| Cash flows from financing activities: | ||||||||
| Proceeds from issuance of long-term debt | — | — | 20,000,000 | — | — | — | 40,000,000 | — |
| Payments on long-term debt and finance lease obligations | — | — | (7,700,000) | — | — | — | (5,400,000) | — |
| Reimbursement of finance lease payments | — | — | — | — | — | — | 1,700,000 | — |
| Purchase of shares | — | — | (1,300,000) | — | — | — | (1,200,000) | — |
| Net cash provided by financing activities | — | — | 11,000,000 | — | — | — | 35,100,000 | — |
| Decrease in cash and cash equivalents | — | — | (10,000,000) | — | — | — | (4,200,000) | — |
| Cash, beginning of period | 31,800,000 | 28,800,000 | 38,800,000 | 21,600,000 | 20,700,000 | 19,200,000 | 23,400,000 | 22,600,000 |
| Cash, end of period | 22,900,000 | 31,800,000 | 28,800,000 | 38,800,000 | 21,600,000 | 20,700,000 | 19,200,000 | 23,400,000 |
| Supplemental disclosures of cash flow information: | ||||||||
| Cash paid during the periods for interest, net | — | — | 24,300,000 | — | — | — | 19,300,000 | — |
| Insurance proceeds received for business interruption | — | — | 500,000 | — | — | — | — | — |
| Indemnification proceeds received for patent litigation | — | — | 500,000 | — | — | — | — | — |
| Non-cash operating activities: | ||||||||
| Operating lease additions | — | — | 1,400,000 | — | — | — | 2,500,000 | — |
| Non-cash investing and financing activities: | ||||||||
| Finance lease additions | — | — | 2,900,000 | — | — | — | 500,000 | — |
| Excise tax payable | — | — | — | — | — | — | 400,000 | — |
| Capital expenditures within accounts payable and accruals | — | — | 30,400,000 | — | — | — | 41,400,000 | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.